Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06757010 · ClinicalTrials.gov registry record · Phase 2

A Study of NE3107 in Early Parkinson's

A Phase 2 study of Parkinsons Disease (PD), sponsored by BioVie.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
4
Study locations

NCT06757010 is a Phase 2 study of Parkinsons Disease (PD) that is actively recruiting participants, run by BioVie. The registered enrollment target is 60 participants, below the 116-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (48% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06757010, a Phase 2 study of Parkinsons Disease (PD), is actively recruiting participants, sponsored by BioVie.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
4
Study locations

Study Summary

The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants have when taking bezisterim? Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease. Participants will * have a physical examination that includes an electrocardiogram * take drug or placebo twice daily for four months * visit a clinical site or receive an at home visit seven times over the course of five months

Conditions Studied

Parkinsons Disease (PD)

Interventions

  • DRUG Placebo
  • DRUG NE3107

Study Locations (4)

Michigan

  • Quest Research Institute - Farmington Hills

New York

  • Dent Neurologic - Amherst

North Carolina

  • Science 37 (Nationwide Site) - Morrisville

Ohio

  • NeuroScience Research Center, LLC - Canton

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-03-26
Est. Completion 2026-01-02
Phase Phase 2

Sponsor

BioVie

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06757010

The ClinicalTrials.gov registry entry for NCT06757010 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (48% lower). The listed sponsor is BioVie, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06757010 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06757010 about?

NCT06757010 is a clinical study titled "A Study of NE3107 in Early Parkinson's". The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any fo...

What is the current status of trial NCT06757010?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03-26. Estimated completion is 2026-01-02.

What conditions does trial NCT06757010 study?

This clinical trial studies the following conditions: Parkinsons Disease (PD).

What interventions are being tested in trial NCT06757010?

The interventions under investigation include: Placebo (DRUG), NE3107 (DRUG).

Who is sponsoring clinical trial NCT06757010?

This trial is sponsored by BioVie, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06757010 being conducted?

This trial has 4 study locations across Michigan, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinsons Disease (PD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinsons Disease (PD)

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.